CT-155 (Boehringer Ingelheim and Click Therapeutics), an investigational prescription digital therapeutic, was both safe and effective in reducing negative symptoms of schizophrenia in a new phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback